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ABSTRACT
The aim of this study was to assess the prevalence of genetic changes in either the HIV reverse
transcriptase (RT) or protease (Pro) genes in a cohort of patients naı¨ve for anti-retroviral therapy. Of 61
patients, 43 (70.5%) were infected with HIV strains harbouring at least one resistance-related mutation,
with 41 (67.2%) harbouring newly recognised treatment-related mutations. Among the 61 patients, the
prevalence of specific mutations in the RT gene was as follows: 39A, 1.6%; 43E, 1.6%; and 228H, 1.6%.
The prevalence of specific mutations in the Pro gene was as follows: 11I, 1.6%; 13V, 26.2%; 35D, 19.6%;
45R, 1.6%; 58E, 1.6%; 62V, 31%; 72V, 11.4%; 72M, 6.5%; 72T, 3.2%; 75I, 1.6%; and 89M, 13%. A higher
prevalence of newly recognised mutations was found in strains from patients infected through sexual
practices (30 ⁄ 36 = 83.4% vs. 11 ⁄ 25 = 44%; p 0.0023; OR 10.91; 95% CI 3.14–40.39). These findings
support the use of resistance testing in patients naı¨ve for anti-retroviral therapy, and suggest that the
possible impact of newly recognised treatment-related mutations on clinical outcome requires further
investigation.
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INTRODUCTION
The advent of highly active anti-retroviral therapy
has resulted in significant reductions in oppor-
tunistic infections and deaths among HIV-posit-
ive patients. These benefits continue, but the
incidence of treatment failures is increasing,
mainly because of the emergence of HIV drug
resistance mutations [1]. These mutations may
also be present in therapy-naı¨ve patients, either
from a stochastic process or following transmis-
sion from index patients. The clinical impact of
these mutations has been demonstrated by evi-
dence from patients harbouring resistant strains
of the prolonged time required to reach an
undetectable viral load and the higher risk of
virological relapse [2].
The prevalence of resistance mutations in ther-
apy-naı¨ve patients may vary depending on the
country in which a survey is conducted, epide-
miological features (e.g., drug exposure and
treatment response at a population level, risk
factors for HIV transmission), technical features
(type of test used and mutations considered to
predict resistance) and the duration of HIV
infection [3]. Secondary mutations or natural
polymorphisms at numerous protease codons
have been identified in therapy-naı¨ve HIV
patients, with possible implications for viral
fitness evolution and response to anti-retroviral
therapy [4–6]. The possibility of novel mutations
in either the reverse transcriptase (RT) [7] or the
protease (Pro) [8] genes has been suggested
following treatment exposure, but few data have
been collected regarding their prevalence in ther-
apy-naı¨ve patients.
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The aim of this study was to assess the
prevalence of any amino-acid changes resulting
from mutations in either the RT or in the Pro gene
in a cohort of patients naı¨ve for anti-retroviral
therapy. A second aim was to assess whether
these changes were related to epidemiological
and clinical characteristics among the patients in
the study cohort.
MATERIALS AND METHODS
Patients were identified from the clinical and genotypic
database at the Institute of Infectious and Tropical Diseases
(Brescia, northern Italy). Each patient was interviewed to
confirm that no anti-retroviral agents had been prescribed
previously. Patients were stratified into two groups by time of
infection: acute or recently infected patients, and patients
whose duration of HIV infection was either unknown or
> 1 year. Patients were also stratified by gender, risk factors for
HIV acquisition (intravenous drug use), HIV viral load
(£ 10 000 or > 10 000 copies ⁄mL plasma), CD4+ T-cell count
(£ 200 or > 200 cells ⁄mL) at the time of resistance testing, and
the time when resistance testing was performed (last calendar
year or before; May 2002 to May 2003; or April 1998 to April
2002).
HIV genotyping was performed with a TRUGENE HIV-1
Genotyping kit (Bayer Diagnostics, Milan, Italy). Amino-acid
substitutions were categorised into five different groups: (1)
mutations known to confer resistance to anti-retroviral drugs,
as listed on the International AIDS Society (IAS) mutation list
[9], plus the mutation V179D in the RT gene, which is not listed
by the IAS, but which is responsible for low-level resistance to
each of the non-nucleoside RT inhibitors (NNRTIs) [10], but
since mutation L63P in the Pro gene does not cause any
appreciable increase in the phenotypic resistance for any
protease inhibitor (PI) [11], this mutation was considered to be
a polymorphism; (2) mutations that have been identified
recently as treatment-related (i.e., their prevalence increases
according to the number of drugs prescribed) [7,8]; (3) any
amino-acid variations, compared to the wild-type, that
occurred at codon positions listed by the IAS, but which
differed from the specific amino-acid change listed by the IAS
(i.e., atypical IAS mutations) [9]; (4) silent nucleotide changes
at codon positions listed by the IAS (i.e., a nucleotide change
that did not result in an amino-acid change with respect to the
HIV wild-type reference sequence); and (5) amino-acid sub-
stitutions at positions not listed by the IAS or recognised as
resistance-related to date (i.e., polymorphisms).
Mutation patterns were interpreted with the TRUGENE
HIV-1 Genotyping Test Resistance Report (Guidelines 5.0)
rules-based algorithm (Bayer Diagnostics). This system uses
three categories to predict HIV drug susceptibility: resistance,
possible resistance, and sensitivity. In this study, resistance
and possible resistance results were grouped together for
analysis. Viral subtypes were determined by comparing HIV
pol sequences with the HIV reference sequence using a BLAST
database search (http://www.hiv.lanl.gov/content/hiv-b/
basic_blast/basic_blast.htm). Viraemia was determined with
the VERSANT HIV-1 RNA 3.0 bDNA Assay with a System
340 bDNA Analyzer (Bayer Diagnostics). Chi-squared tests
were used to compare the prevalence of resistance between
stratification groups (see above), with p < 0.05 considered to
indicate statistical significance.
RESULTS
Sixty-one patients were included in the study
between April 1998 and May 2003. Patient char-
acteristics at the time of resistance testing are
listed in Table 1.
All of the patients harboured viruses with at
least one amino-acid change, with respect to the
wild-type, in either the RT gene or the Pro gene.
Among the 61 patients, 43 (70.5%) were infected
with HIV carrying at least one mutation either
listed by the IAS or resistance-related (six (9.8%)
to nucleoside or nucleotide reverse transcriptase
inhibitors (N(t)RTIs), five (8.2%) to NNRTIs, and
40 (65.5%) to PIs; Table 2). Ten (16.4%) HIV
isolates had at least one IAS or resistance-related
mutation in the RT gene. No major mutations
listed by the IAS were found in the Pro gene.
The TRUGENE HIV-1 rules-based interpret-
ation system did not predict resistance to any of
the PIs. However, in the RT gene, the prevalence
of resistance to N(t)RTIs, as interpreted by TRU-
GENE, correlated with the prevalence of IAS or
resistance-related mutations (Table 2). Ten
(16.4%) HIV resistance patterns were interpreted
as resistance to at least one RT inhibitor. With
respect to particular N(t)RTIs, the prevalence of
resistance indicated by TRUGENE interpretation
Table 1. Characteristics of the 61 patients included in the
study
Characteristic Patients
Age (years)
Median (IQR) 37 (23–64)
Gender; n (%)
Male 48 (78.7%)
Female 13 (21.3%)
HIV transmission category; n (%)
IVDU 25 (41.0%)
Not IVDU 36 (59.0%)
CD4+ cell count (cells ⁄mm3)
Median (IQR) 289 (4–992)
Patients with CD4+ count £ 200 cells ⁄mm3 14 (23.0%)
HIV RNA (copies ⁄mL)
Median (IQR) 21 000 (500–750 000)
Patients with HIV RNA £ 10 000 copies ⁄mL 21 (34.4%)
Time of infection; n (%)
Acute or recent (£ 1 year) 10 (16.4%)
Chronic or unknown 51 (83.6%)
Time of testing; n (%)
Last year 31 (50.8%)
Previous years 30 (49.2%)
Viral subtype; n (%)
B 56 (91.8%)
Others 5 (8.2%)
IQR, interquartile range; IVDU, intravenous drug use.
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was highest for zidovudine (4 ⁄ 6), and lowest for
stavudine and tenofovir (1 ⁄ 6 for both drugs). For
NNRTIs, the TRUGENE system successfully pre-
dicted all five patients with viruses resistant to
nevirapine, delavirdine and efavirenz. Only one
strain, from a patient with acute HIV infection,
had multidrug resistance to both NNRTI and
N(t)RTI classes.
The prevalence of newly recognised treat-
ment-related mutations in the Pro gene was
high, with three (4.9%) patients having at least
one such mutation conferring resistance to
N(t)RTIs, and 40 patients (65.5%) having at least
one such mutation conferring resistance to PIs
(Table 2). Specific mutations in the Pro gene
were as follows: 11I, 1.6%; 13V, 26.2%; 35D,
19.6%; 45R, 1.6%; 58E, 1.6%; 62V, 31%; 72V,
11.4%; 72M, 6.5%; 72T, 3.2%; 75I, 1.6%; and
89M, 13%. In the RT gene, newly identified
treatment-related mutations were as follows:
39A, 1.6%; 43E, 1.6%; and 228H, 1.6%.
Atypical mutations at codon positions listed by
the IAS were found either in mixed populations
together with a major mutation (i.e., 36I ⁄L) or
singly (i.e., 67G, 75L and 215D ⁄C in the RT gene,
and 20I and 82I in the Pro gene). Only mutations
listed by the IAS, or resistance-related mutations,
were found at other positions (i.e., 41, 69, 103, 108,
179, 181, 184, 210 and 219 in the RT gene, and 10,
71 and 77 in the Pro gene; Fig. 1).
Following stratification by relevant epidemio-
logical and clinical features (including HIV sub-
type), the only statistically significant difference
was a higher prevalence of the newly recognised
treatment-related mutations in strains from
patients infected through sexual practices, as
opposed to intravenous drug use (30 ⁄ 36 =
83.4% vs. 11 ⁄ 25 = 44%; p 0.0023; OR 10.91; 95%
CI 3.14–40.39).
DISCUSSION
Mutations conferring resistance to anti-retroviral
drugs exert a negative impact on the virological
response to highly active anti-retroviral therapy,
both in patients who have received anti-retroviral
therapy previously (secondary resistance) and in
therapy-naı¨ve patients (primary resistance) [2].
Since the end of 1990, the prevalence of primary
resistance in the USA and Europe has been
increasing. Thus, in the USA, the prevalence
increased from 3.4% in 1995 to 12.4% in 2000
[2]. However, an opposite trend has been dem-
onstrated in certain countries, e.g., Switzerland,
where the prevalence of primary resistance was
8.6%, 14.6%, 8.8% and 5.5% in 1996, 1997, 1998
and 1999, respectively [12], while a large colla-
borative multinational study found a primary
resistance prevalence of c. 10% across Europe
[13]. In the present study involving 61 patients,
the overall prevalence of primary resistance
mutations considered in the IAS resistance tables
to be resistance-related [9] was 16.4% after the
exclusion of minor mutations found in the Pro
gene. The rules-based TRUGENE algorithm sug-
gested a 16.4% prevalence of resistance, support-
Table 2. Genotypic changes and
related rules-based interpretation in
HIV strains
Resistance N(t)RTI NNRTI PI
TRUGENE predictiona 6 ⁄ 61 (9.8%) 5 ⁄ 61 (8.2%) 0 ⁄ 61 (0%)
IASb or resistance-related
mutations
6 ⁄ 61 (9.8%) 5 ⁄ 61 (8.2%) 40 ⁄ 61 (65.5%)
Recently identified
treatment-related mutationsc
3 ⁄ 61 (4.9%) 0 ⁄ 61 (0%) 40 ⁄ 61 (65.5%)
Atypical mutations
at IAS positionsd
4 ⁄ 61 (6.5%) 2 ⁄ 61 (3.2%) 8 ⁄ 61 (13.1%)
Silent nucleotide substitutionse 43 ⁄ 61 (70.5%) 32 ⁄ 61 (52.4%) 37 ⁄ 61 (60.6%)
Polymorphismsf 60 ⁄ 61 (98.4%) 34 ⁄ 61 (55.7%) 60 ⁄ 61 (98.4%)
Total (any of the above) 60 ⁄ 61 (98.4%) 48 ⁄ 61 (78.6%) 61 ⁄ 61 (100%)
N(t)RTI, nucleoside (nucleotide) reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor.
aResistance patterns interpreted by the TRUGENE HIV-1 Genotyping Test Resistance Report (Guidelines 5.0).
‘Resistant’ and ‘possible resistant’ results are ranked together for the prevalence count.
bMutations known to confer resistance to anti-retroviral drugs as listed by the International Aids Society (IAS) [9].
Prevalence includes V179D in the RT gene [10], but excludes L63P in the Pro gene, which is currently considered to
be a natural polymorphism [11].
cRecently identified treatment-related mutations [7, 8].
dAmino-acid changes at positions indicated by the IAS, but different from the specific changes indicated [9].
eMutations at the codon positions listed by the IAS, but which do not correspond to amino-acid substitutions.
fAmino-acid changes at positions neither indicated by the IAS nor recognised as resistance-related, including those
at position 63 in the Pro gene, found in 45 (73.8%) patient isolates. L63P was found in 36 (59%) cases. At this
position, amino-acids AFIQST have also been found. R57K has been associated with a high rate of virological failure
in patients prescribed regimens containing a PI (especially nelfinavir) [6]; this mutation was found in eight (13.1%)
of 61 patients.
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ing the possible relevance of resistance testing in
anti-retroviral-naı¨ve patients.
Even though protease resistance patterns were
not interpreted as conferring resistance by the
rules-based algorithm used, some minor muta-
tions found at high prevalence, such as those at
positions 10 or 36, have been associated with
increased risk of virological failure [5]. More-
over, one study [6] has associated the presence
of polymorphism R57K in the protease gene at
baseline with early virological failure in anti-
retroviral-naı¨ve patients commencing first-line
therapy containing PIs (mainly nelfinavir), and
this polymorphism was found in eight (13.1%)
isolates from plasma in the present cohort. In
some resistance positions listed by the IAS
(positions 67, 75 and 215 in the RT gene, and
positions 20, 36, 63 and 82 in the Pro gene),
substitutions were found that are not considered
by the IAS to be resistance-related. Some of
these mutations (e.g., so-called ‘revertant’ muta-
tions at position 215) have been associated with
a risk of virological failure in previously ther-
apy-naı¨ve patients [14]. Overall, these findings
suggest that the broad spectrum of mutations
that may occur at high prevalence in therapy-
naı¨ve patients should be investigated further to
assess their possible impact on the virological
treatment response.
Interestingly, a high prevalence of newly rec-
ognised treatment-related mutations was found in
the present cohort, either in the RT gene [7] or in
the Pro [8] gene. In the RT gene, positions 43 and
228 were invariably conserved in the HIV genome
in therapy-naı¨ve patients in the reference study
[7], while 43E and 228H mutations were found,
albeit at low frequencies, in the present study.
More striking was the observation that mutations
at positions 11, 35 and 45 in the Pro gene were
found at a prevalence comparable to that in
patients treated with at least two PIs, while
mutations at positions 72 and 89 were found at
a prevalence comparable to that in patients trea-
ted with at least four PIs [8]. In addition, substi-
tutions at positions 45 and 58 in the Pro gene were
never found in a large population of naı¨ve
patients [15], while they were found at a low
frequency in the present study. The possibility
that these mutations involving fitness or pheno-
typic resistance traits may then promote persist-
ence or accumulation of further mutations, in turn
increasing the risk of virological failure, remains
to be elucidated in further studies.
The prevalence of newly identified treatment-
related mutations was significantly higher in
patients who acquired HIV infection through
sexual practices, as opposed to intravenous drug
use. Several factors may have an impact on the
transmissibility of resistant strains. It is generally
thought [16,17] that resistant HIV strains are less
transmissible because of a negative impact of
major resistance mutations, either on viral fitness
(which contributes to an explanation of the
lower viral load found in patients under drug
selective pressure) or on the molecular mecha-
nisms involved in transmission. It has been
demonstrated that some minor mutations can
restore viral fitness that has been compromised
by other mutations [4]. To complicate this matter
further, compartmentalisation of resistance
strains in the genital system may be favoured
by weak penetration of active drugs and a poor
immune response at these sites. The complexity
of this issue means that it is difficult to identify
the factors that explain the high prevalence of
newly identified treatment-related mutations,
especially in patients infected through sexual
practices. However, it can be hypothesised that
these new mutations could also have a role in
improving transmission fitness via the sexual
route.
Fig. 1. Prevalence of mutations (both canonical and atyp-
ical) at positions indicated by the International AIDS
Society (IAS) in HIV strains from the study patients.
N(t)RTI, nucleoside (nucleotide) reverse transcriptase
inhibitor; NNRTI, non-nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor.
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The present study had several limitations.
First, the sample size was small and, since all
the patients were recruited from a limited area,
the results cannot necessarily be applied to other
geographical areas. Second, the study was ret-
rospective and no results on the treatment
outcome of the patients studied were available.
Thus, although a high prevalence of known
mutations or newly recognised treatment-related
mutations was found in therapy-naı¨ve patients,
further prospective studies that address the
possible clinical impact of these mutations are
required to provide information on the clinical
utility of resistance testing in these circum-
stances.
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